Passage Bio, Inc.

Passage Bio, Inc.

NNASDAQ:PASG
4.13
USD
-0.12
(-2.82%)
-10.33EPS
14.48MMarket Cap
Mar 08Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-10.66
-23.17
-49.21
-69.51
-50.02
-37.29
-21.44
-14.35
-10.33
Free Cash Flow per Basic Share
-17.62
-21.11
-36.03
-57.18
-45.37
-28.65
-15.89
-9.93
-10.19
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-6.18
-28.56
133.6
117.49
73.74
40.51
19.74
5.89
0.02
Tangible Book Value per Share
-6.18
-28.56
133.6
117.49
73.74
40.51
19.74
5.89
0.02
Basic Weighted Avg Shares
1
2
2
3
3
3
3
3
3
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
1
2
4
4
3
1
- -
Net Income, GAAP
-13
-46
-112
-185
-136
-102
-65
-46
-33
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
33
162
296
296
179
102
59
25
- -
LT Debt
- -
- -
- -
- -
24
23
22
20
- -
Total Equity
-12
-56
305
319
201
111
61
19
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-59.48
-52.35
-65.29
-75.07
-113.78
-212.27

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
5
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
25
16
14

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
35
25
21
Cash, Cash Equivalents & STI
33
24
20
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
20
21
21
Payables & Accruals
4
3
3
ST Debt
1
- -
- -
Deferred Revenue
14
16
17

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-38.26%
-69.39%
Free Cash Flow
- -
-8.61%
-34.34%
Net Income, GAAP
- -
-10.53%
-29.71%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-5.94
-5.09
-6.15
-4.1
-21.44
2025
-4.87
-2.96
-2.44
-4.08
-14.35
2026
-2.36
-2.44
-1.47
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
William Chou
Full Time Employees
24
Sector
Health technology
Industry
Biotechnology
Address
One Commerce Square Philadelphia PA United States 19103
IPO Date
Feb 28, 2020
Business
Passage Bio, Inc. is a clinical-stage genetic medicines company specializing in the development and advancement of one-time gene therapies targeting neurodegenerative diseases and rare monogenic central nervous system (CNS) disorders. The company develops and offers multiple gene therapy candidates including PBGM01, a functional GLB1 gene therapy encoding β-galactosidase for the treatment of infantile GM1 gangliosidosis; PBFT02, a functional granulin gene encoding progranulin for frontotemporal dementia caused by progranulin deficiency; PBKR03, a functional GALC gene therapy encoding galactosylceramidase for infantile Krabbe disease; PBML04 for metachromatic leukodystrophy; and PBAL05 for amyotrophic lateral sclerosis, with additional programs targeting Huntington’s disease. Passage Bio operates primarily in the United States and maintains a strategic research collaboration and licensing agreement with the University of Pennsylvania's Gene Therapy Program for discovery and preclinical development work. Its manufacturing capabilities are supported through a partnership with Catalent Maryland, Inc., which includes dedicated cGMP manufacturing, packaging, labeling, and distribution services for its gene therapy products. Founded in 2017 and headquartered in Philadelphia, Pennsylvania, Passage Bio is focused on transitioning from preclinical to clinical stages with several programs in clinical development. Recent major company changes include leadership transitions with a new executive team, advancement in clinical trials notably the ongoing multinational Phase 1/2 upliFT-D study evaluating PBFT02 for frontotemporal dementia, and the strategic narrowing of its pediatric lysosomal storage disease pipeline for focused development and potential partnerships. The company has also progressed its manufacturing operations by establishing a dedicated cGMP suite with Catalent to ensure scalable production capacity and supply chain control critical for clinical and future commercial needs. Passage Bio continuously optimizes its pipeline and explores partnerships to accelerate the development and accessibility of its gene therapy candidates for rare CNS diseases.

Company News

  • $HAREHOLDER ALERT: The M&A Class Action Firm Launches Investigation for the Merger — BWMN, UTZ , PASG and FNWD

  • MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWD

  • PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders

  • PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders

  • $HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWD

  • Passage Bio, Inc. (NASDAQ:PASG) Stock Has Average Price Target of $13.25 According to Brokerages

  • Passage Bio (NASDAQ:PASG) Stock Falls 2.4% – Here’s What Happened

  • Analysts Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $13.25

  • Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript

  • Passage Bio and Remix Therapeutics Announce Merger Agreement

  • Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

  • Analysts Set Passage Bio, Inc. (NASDAQ:PASG) PT at $42.67

  • Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

  • Passage Bio to Participate in Upcoming Investor Conferences

  • Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67

  • Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $42.67

  • Analyzing Passage Bio (NASDAQ:PASG) and Vir Biotechnology (NASDAQ:VIR)

  • Financial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG)

  • Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67

  • Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights